Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction

Ajith Nair, Anita Deswal

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

More than 50% of patients with clinical heart failure have a preserved ejection fraction. Despite mortality that is similar to or slightly lower than heart failure with reduced ejection fraction, trials to date have not shown a therapy that imparts a mortality benefit in heart failure with preserved ejection fraction (HFpEF). HFpEF represents a heterogeneous disorder with a complex pathophysiologic basis, and this may contribute to the negative results in clinical trials. Geographic variations in both patient selection and adherence to study medications confound the interpretation of the trial results. Mineralocorticoid receptor antagonists may be useful in selected patients.

Original languageEnglish (US)
Pages (from-to)525-535
Number of pages11
JournalHeart Failure Clinics
Volume14
Issue number4
DOIs
StatePublished - Oct 2018

Keywords

  • Aldosterone blocker
  • Eplerenone
  • Heart failure
  • Heart failure with preserved ejection fraction
  • Spironolactone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction'. Together they form a unique fingerprint.

Cite this